|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP), and orotate phosphoribosyltransferase (OPRT) have been reported to be predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy. mRNA expression of TS, DPD, TP, and OPRT were quantified by reverse-transcriptase polymerase chain reaction after harvesting cancer cells from 93 paraffin-embedded specimens of gastric cancer through laser capture microdissection.
|
17303323 |
2007 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer.
|
17854149 |
2007 |
|
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results show that the presence of the TS 3'-UTR 6 bp nucleotide fragment can be correlated with the sensitivity of gastric cancer to 5-FU-based chemotherapy, and that the TS 3'-UTR polymorphism profile can be used to guide the choice of 5-FU-based chemotherapy in advanced gastric cancer.
|
16424979 |
2006 |
|
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the TYMS polymorphisms, especially the TS3'UTR polymorphism, are associated with GC risk, especially the non-cardiac gastric cancer, and the TSER 2R and TS3'UTR 6 bp alleles may jointly play a role in the etiology of GC in the southern Chinese population.
|
15930032 |
2005 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The prognostic role of TS polymorphisms in gastric cancer deserves further investigation because the adverse effect of high TS expression genotypes may be a relevant information to improve adjuvant chemotherapeutic strategies.
|
15897576 |
2005 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
While TS genotype affected TS mRNA expression in both normal and tumor tissues in advanced gastric cancer, there is no relationship between TS genotype or mRNA expression level and 5-FU chemosensitivity.
|
15330198 |
2004 |
|
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association of thymidylate synthase polymorphisms with gastric cancer susceptibility.
|
15386366 |
2004 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer.
|
15316940 |
2004 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer.
|
15354215 |
2004 |
|
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present results suggest that TS polymorphism may modify the risk of esophageal and stomach cancer with smoking, pointing to the necessity for further investigations with information on folate and methionine intake with a larger population.
|
15244514 |
2004 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer.
|
12530000 |
2003 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR.
|
12495474 |
2002 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion.
|
11445849 |
2001 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results of immunohistochemical staining for TS and p53 showed no relation between these two protein expressions in endoscopic biopsy specimens of 25 patients with advanced gastric cancer.
|
11445854 |
2001 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Biopsy specimens of gastric cancer were obtained preoperatively through gastrofiberscopy and used to determine TS and DPD messenger RNA (mRNA) levels.
|
10744051 |
2000 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Biopsy specimens of gastric cancer were obtained preoperatively through gastrofiberscopy and used to determine TS and DPD mRNA levels.
|
10697632 |
2000 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.
|
9440758 |
1998 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Results of other studies of adjuvant therapy in gastric cancer and colorectal cancer also indicated that TS expression within the tumor is predictive of response of 5-FU-based therapy.
|
9726090 |
1998 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Sixty-five patients with primary gastric cancer had a median TS mRNA level of 4.6 x 10(-3) (range, 0.9 to 20.1 x 10(-3)).
|
8558194 |
1996 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A randomized study was conducted to investigate schedule-dependent thymidylate synthase (TS) inhibition by 5-FU in 16 patients with gastric cancer who underwent surgical resection.
|
1451052 |
1992 |